Ultraceuticals takes on Europe

Ultraceuticals founder Dr Geoffrey Heber and CEO Karen Wilkin-Donachie with Renaissance Products GM Michael Evans and Ultraceuticals BDM Helene Floury 

Ultraceuticals has secured a distribution agreement with one of Ireland’s leading skincare distributors, Renaissance Products, in a move that will see it enter the European market for the first time.

Announcing the signing of the distribution deal, Ultraceuticals CEO Karen Wilkin-Donachie said the company’s products would land in Ireland this month.

“We are proud to have the best possible partner with Renaissance to represent us in Ireland and help launch into this very high-quality skincare market,” she said.

“The Irish market, whilst smaller in size, is very well known for its high-calibre beauty therapists and very strong attention to their skin within this market.

“We also feel we’re going to learn a lot in Ireland that will certainly assist with our growth plans throughout the rest of Europe in the future.”

Renaissance’s general manager Michael Evans said the company had been searching for “a really good advanced cosmeceutical skincare brand” to add to its product porfolio (which currently includes Yon-ka Paris and Image Skincare) for three years.

“We needed a brand that Irish people could identify with and felt that there is a great connection between the two countries,” he said.

“The professionalism and passion are amazing in Australia. Many Irish therapists who have worked in the country are impressed at the advanced level of the skincare in the market.”

Evans added that the company believes that Irish skincare professionals and their clients will be impressed with the brand’s products and treatments.

“We see Ultraceuticals providing professionals with a high-quality solution to people’s skincare needs.

“We know everyone will be impressed with the results and with our support it will be a huge success for those who partner with us in Ireland.”

For more news and updates, subscribe to our weekly newsletter.

 

 

 

Leave a comment: